



The San Diego Chemist

American Chemical Society
Volume 30, Number 9

San Diego Section
September 2018



7th SABPA/ACS Chemistry Symposium



DATE: Thursday, September 6, 2018

TIME: 6:00 – 6:30 PM Registration, Networking and Light dinner

6:30 – 7:15 PM Dr. Jinglan Zhou

Discovery of Ivacaftor, a CFTR Potentiator for the Treatment of Cystic Fibrosis

7:15 – 8:00 PM Professor John L. Wood

Recent Efforts in the Synthesis of Complex Natural Products

PLACE: Lilly Biotechnology Center, 10290 Campus Point Drive., San Diego, CA 92121

Free registration: <https://www.eventbrite.com/e/7th-sabpaacs-chemistry-symposium-tickets-48071197245>

Attendance is by pre-registration only – no walk-ins please.


Speakers:

John L. Wood is the Robert A. Welch Distinguished Professor of Chemistry and Biochemistry at Baylor University. He is also a Cancer Prevention Research Institute of Texas (CPRIT) Scholar and an Associate Editor for Tetrahedron Letters.



Wood received a B.A. degree from the University of Colorado in 1985 and a Ph.D. from the University of Pennsylvania in 1991. He then moved to Harvard University as an American Cancer Society postdoctoral fellow and continued studying natural products synthesis in the laboratories of Stuart Schreiber. He joined the faculty at Yale University in 1993 as an assistant professor and was promoted to full professor in 1998. In 2006, he joined the faculty at Colorado State University as the Albert I. Meyers Professor of Chemistry. In 2013, Wood moved from Colorado State to Baylor. In the words of Dr. Elizabeth Davis, executive vice president and provost at Baylor University, "Dr. Wood is an outstanding scientist and educator. He has an impressive academic research career and a great reputation as a teacher and mentor. Dr. Wood has a passion for chemistry, and his work promises to push forward the frontiers of cancer research."

Jinglan Zhou, PhD, Research Fellow I, Vertex Pharmaceuticals Incorporated



Dr. Jinglan Zhou obtained a B.S. and M.S. in chemistry from Sichuan University, China. After earning a Ph.D. from Auburn University in 1997 under the direction of Prof. Philip Shevlin, Jinglan joined CombiChem in 1998 which was acquired by DuPont Pharmaceuticals, BMS and Deltagen, respectively. Jinglan then spent a year at Anadys Pharmaceuticals and moved to Vertex Pharmaceuticals in 2004 where she is currently a Research Fellow I. During her career at Vertex, Jinglan has contributed to the advancement of >10 clinical candidates in the areas of cystic fibrosis and pain. Jinglan was a key member of the chemistry team that discovered Ivacaftor (VX-770), Lumacaftor (VX-809) and Tezacaftor (VX-661), the three marketed drugs for the treatment of cystic fibrosis. Together with her teammates, Jinglan received the Heroes of Chemistry award from American Chemistry Society in 2013 owing to her contributions to Ivacaftor, the first medicine to treat the underlying cause of cystic fibrosis. Jinglan is an author/inventor on over 45 publications/patents.

